FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Prostate Cancer
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: people with metastatic or recurrent cancer
In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-Low
Research Timeline: Human Research
Update : Blood tests called liquid biopsies for cancer screening, monitoring and treatment
Most relevant for: People considering a liquid biopsy to screen for cancer
Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Quality of Writing: High
Article : Transgender peoples' perspectives of being diagnosed with gender-associated cancer
Most relevant for: transgender people
An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Test score may predict which prostate cancer patients can safely skip combined therapy
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Men with advanced prostate cancer
This study shows that a test score that estimates the aggressiveness of a person’s prostate cancer may also identify the best treatment for patients. (posted 7/9/21)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Cancer risks of people with inherited PALB2 mutations
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: people with inherited PALB2 mutations
In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People concerned about their risk of colorectal or ovarian cancer.
This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use:
- lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
- lowered the risk of ovarian cancer risk among obese women.
- offered little or no protection against breast, endometrial or advanced prostate cancer.
(posted 3/19/21)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Update : FDA approves Orgovyx, the first oral hormone therapy of its type for treating advanced prostate cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: Men with advanced prostate cancer
In December 2020, the FDA approved Orgovyx to treat advanced prostate cancer. The findings were based on the HERO clinical trial of more than 900 men. Data from this trial showed the new therapy was safer than standard androgen deprivation treatment for men with advanced prostate cancer and risk of cardiovascular disease. (2/18/21)
Este artículo está disponible en español.
Read More
Relevance: High
Research Timeline: Post Approval
Update : FDA approves new imaging drug for detecting spread of prostate cancer
Most relevant for: Men with prostate cancer
On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)
THIS INFORMATION HAS BEEN UPDATED on 5/10/2022: On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : New imaging technology shows promise in detecting of spread of prostate cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Men with high-risk prostate cancer
A new imaging technique is currently being tested to see if it can detect the spread of prostate cancer sooner than standard imaging. Two clinical trials show that the new technique can detect the spread of prostate cancer in men who are newly diagnosed and in men whose cancer returns after treatment. (10/16/20)
Read More
Relevance: High
Quality of Writing: High
Personal Story : Coping with chemotherapy-induced hair loss
Most relevant for: People who receive chemotherapy for cancer treatment
Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)
Read More
Search XRAY studies and Articles
This Portal Sponsored By:
